{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:50:40Z","timestamp":1777949440134,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02683-8","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:01:45Z","timestamp":1777852905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Total neoadjuvant chemotherapy combined with PD\u20111 blockade and IL\u20112 in MSS\/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study"],"prefix":"10.1038","volume":"11","author":[{"given":"Junwei","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangpeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-134X","authenticated-orcid":false,"given":"Yueming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2683_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz, S. et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat. Med. 31, 901\u2013908 (2025).","journal-title":"Nat. Med."},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467\u20131480 (2019).","journal-title":"Lancet"},{"key":"2683_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO-24-01676","volume":"43","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. J. Clin. Oncol. 43, 633\u2013640 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2683_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2468-1253(22)00156-X","volume":"7","author":"R Qu","year":"2022","unstructured":"Qu, R., Ma, Y., Zhang, Z. & Fu, W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol. Hepatol. 7, 700 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S1470-2045(14)70398-5","volume":"16","author":"CA Marijnen","year":"2015","unstructured":"Marijnen, C. A. Organ preservation in rectal cancer: have all questions been answered?. Lancet Oncol. 16, e13\u2013e22 (2015).","journal-title":"Lancet Oncol."},{"key":"2683_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2683_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr.","year":"2022","unstructured":"Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670 (2022).","journal-title":"Lancet Oncol."},{"key":"2683_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med."},{"key":"2683_CR9","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.23.02261","volume":"42","author":"F Xia","year":"2024","unstructured":"Xia, F. et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). J. Clin. Oncol. 42, 3308\u20133318 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2683_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","volume":"9","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct. Target Ther. 9, 56 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2683_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/bjs.7315","volume":"98","author":"HA Swellengrebel","year":"2011","unstructured":"Swellengrebel, H. A. et al. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. Br. J. Surg. 98, 418\u2013426 (2011).","journal-title":"Br. J. Surg."},{"key":"2683_CR12","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KC Peeters","year":"2005","unstructured":"Peeters, K. C. et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study. J. Clin. Oncol. 23, 6199\u20136206 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2683_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322\u2013334 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2683_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.trecan.2024.11.011","volume":"11","author":"K Ma","year":"2025","unstructured":"Ma, K. et al. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends Cancer 11, 117\u2013134 (2025).","journal-title":"Trends Cancer"},{"key":"2683_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","volume":"22","author":"R Hernandez","year":"2022","unstructured":"Hernandez, R., Poder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614\u2013628 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","volume":"56","author":"M Tichet","year":"2023","unstructured":"Tichet, M. et al. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8(+) T cells and reprogramming macrophages. Immunity 56, 162\u2013179.e166 (2023).","journal-title":"Immunity"},{"key":"2683_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine. Nature 484, 529\u2013533 (2012).","journal-title":"Nature"},{"key":"2683_CR18","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. Clin. Cancer Res. 28, 1136\u20131146 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2683_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","volume":"159","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer. JAMA Surg. 159, 529\u2013537 (2024).","journal-title":"JAMA Surg."},{"key":"2683_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JS9.0000000000001960","volume":"111","author":"F Wang","year":"2025","unstructured":"Wang, F. et al. Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study. Int J. Surg. 111, 334\u2013345 (2025).","journal-title":"Int J. Surg."},{"key":"2683_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma, O. E. et al. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 7, 1225\u20131230 (2021).","journal-title":"JAMA Oncol."},{"key":"2683_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","volume":"42","author":"WW Xiao","year":"2024","unstructured":"Xiao, W. W. et al. Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell 42, 1570\u20131581.e1574 (2024).","journal-title":"Cancer Cell"},{"key":"2683_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","volume":"31","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial. Nat. Med. 31, 449\u2013456 (2025).","journal-title":"Nat. Med."},{"key":"2683_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101824","volume":"8","author":"E Grassi","year":"2023","unstructured":"Grassi, E. et al. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open 8, 101824 (2023).","journal-title":"ESMO Open"},{"key":"2683_CR25","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-25-0705","volume":"31","author":"M Michael","year":"2025","unstructured":"Michael, M. et al. The Ave-Rec Trial: Phase II Trial of PDL1\/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4\/N1-2 Rectal Cancer. Clin. Cancer Res. 31, 3452\u20133462 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2683_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702\u2013715 (2021).","journal-title":"Lancet Oncol."},{"key":"2683_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 29\u201342 (2021).","journal-title":"Lancet Oncol."},{"key":"2683_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","volume":"4","author":"W Wu","year":"2023","unstructured":"Wu, W. et al. IL-2Ralpha-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells. Nat. Cancer 4, 1309\u20131325 (2023).","journal-title":"Nat. Cancer"},{"key":"2683_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher, J. P. et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"2683_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","volume":"35","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini, M. et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann. Oncol. 35, 643\u2013655 (2024).","journal-title":"Ann. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02683-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:01:56Z","timestamp":1777852916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02683-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}